{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T13:53:29Z","timestamp":1766411609738,"version":"3.48.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,22]]},"DOI":"10.7759\/cureus.99831","type":"journal-article","created":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T13:48:57Z","timestamp":1766411337000},"source":"Crossref","is-referenced-by-count":0,"title":["Two Cases of Neuroendocrine Transformation of Prostate Carcinoma in the Era of Expanding Therapeutic Options: Do the Increased Number of Available Treatments Translate Into Improved Patient Outcomes?"],"prefix":"10.7759","author":[{"given":"Rita","family":"Aranha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filipe","family":"Veiga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Marques","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joana","family":"Melo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sofia A","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Global Cancer Observatory. Statistics at a glance, 2022. (2022). Accessed: January 20, 2025: https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/populations\/900-world-fact-sheet.pdf."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/cells13231999","article-title":"Therapeutic exploitation of neuroendocrine transdifferentiation drivers in prostate cancer","volume":"13","author":"Maylin ZR","year":"2024","unstructured":"Maylin ZR, Smith C, Classen A, Asim M, Pandha H, Wang Y. Therapeutic exploitation of neuroendocrine transdifferentiation drivers in prostate cancer. Cells. 2024, 13:1999. 10.3390\/cells13231999","journal-title":"Cells"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6880","article-title":"Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study","volume":"36","author":"Aggarwal R","year":"2018","unstructured":"Aggarwal R, Huang J, Alumkal JJ, et al.. Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study. J Clin Oncol. 2018, 36:2492-503. 10.1200\/JCO.2017.77.6880","journal-title":"J Clin Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1172\/JCI164611","article-title":"Deciphering the enigma of neuroendocrine prostate cancer","volume":"132","author":"Karzai F","year":"2022","unstructured":"Karzai F, Madan RA. Deciphering the enigma of neuroendocrine prostate cancer. J Clin Invest. 2022, 132:e164611. 10.1172\/JCI164611","journal-title":"J Clin Invest"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2014.0073","article-title":"Neuroendocrine prostate cancer: subtypes, biology, and clinical outcomes","volume":"12","author":"Aggarwal R","year":"2014","unstructured":"Aggarwal R, Zhang T, Small EJ, Armstrong AJ. Neuroendocrine prostate cancer: subtypes, biology, and clinical outcomes. J Natl Compr Canc Netw. 2014, 12:719-26. 10.6004\/jnccn.2014.0073","journal-title":"J Natl Compr Canc Netw"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney CJ","year":"2015","unstructured":"Sweeney CJ, Chen YH, Carducci M, et al.. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015, 373:737-46. 10.1056\/NEJMoa1503747","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32486-3","article-title":"Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial","volume":"392","author":"Parker CC","year":"2018","unstructured":"Parker CC, James ND, Brawley CD, et al.. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet. 2018, 392:2353-66. 10.1016\/S0140-6736(18)32486-3","journal-title":"Lancet"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0147191","article-title":"Does radiotherapy for the primary tumor benefit prostate cancer patients with distant metastasis at initial diagnosis?","volume":"11","author":"Cho Y","year":"2016","unstructured":"Cho Y, Chang JS, Rha KH, et al.. Does radiotherapy for the primary tumor benefit prostate cancer patients with distant metastasis at initial diagnosis?. PLoS One. 2016, 11:e0147191. 10.1371\/journal.pone.0147191","journal-title":"PLoS One"},{"key":"ref9","unstructured":"Memorial Sloan Kettering Cancer Center. Researching new treatments for neuroendocrine prostate cancer (NEPC). (2025). Accessed: September 18, 2025: https:\/\/www.mskcc.org\/news\/new-treatments-for-neuroendocrine-prostate-cancer-nepc-focus-at-msk."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-25-1211","article-title":"Safety and efficacy of tarlatamab in patients with neuroendocrine prostate cancer: results from the phase 1b DeLLpro-300 study","volume":"31","author":"Aggarwal R","year":"2025","unstructured":"Aggarwal R, Rottey S, Bernard-Tessier A, et al.. Safety and efficacy of tarlatamab in patients with neuroendocrine prostate cancer: results from the phase 1b DeLLpro-300 study. Clin Cancer Res. 2025, 31:3854-63. 10.1158\/1078-0432.CCR-25-1211","journal-title":"Clin Cancer Res"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01055-3","article-title":"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO- 2): a randomized, placebo-controlled, phase 3 trial","volume":"402","author":"Agarwal N","year":"2023","unstructured":"Agarwal N, Azad AA, Carles J, et al.. Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO- 2): a randomized, placebo-controlled, phase 3 trial. Lancet. 2023, 402:291-303. 10.1016\/S0140-6736(23)01055-3","journal-title":"Lancet"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17040682","article-title":"Ancestry-specific DNA damage repair gene mutations and prostate cancer","volume":"17","author":"Borbiev T","year":"2025","unstructured":"Borbiev T, Babcock K, Sinopole K, Chesnut GT, Petrovics G. Ancestry-specific DNA damage repair gene mutations and prostate cancer. Cancers (Basel). 2025, 17:682. 10.3390\/cancers17040682","journal-title":"Cancers (Basel)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/447729-two-cases-of-neuroendocrine-transformation-of-prostate-carcinoma-in-the-era-of-expanding-therapeutic-options-do-the-increased-number-of-available-treatments-translate-into-improved-patient-outcomes","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T13:48:58Z","timestamp":1766411338000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/447729-two-cases-of-neuroendocrine-transformation-of-prostate-carcinoma-in-the-era-of-expanding-therapeutic-options-do-the-increased-number-of-available-treatments-translate-into-improved-patient-outcomes"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,22]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.99831","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,22]]}}}